Tom H M Ottenhoff

List of Publications by Year in Descending Order

307 papers	18,361 citations	74 h-index	124 g-index
329 ext. papers	21,359 ext. citations	8 avg, IF	6.5 L-index

#	Paper	IF	Citations
307	Transcriptomic signatures induced by the Ebola virus vaccine rVSV□-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.. *Lancet Microbe, The*, **2022**, 3, e113-e123	22.2	
306	Effects of BCG vaccination on donor unrestricted T cells in two prospective cohort studies.. *EBioMedicine*, **2022**, 76, 103839	8.8	1
305	Lung epithelial cells interact with immune cells and bacteria to shape the microenvironment in tuberculosis.. *Thorax*, **2022**,	7.3	1
304	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood.. *Molecular Immunology*, **2022**, 145, 17-26	4.3	1
303	Defining Discriminatory Antibody Fingerprints in Active and Latent Tuberculosis.. *Frontiers in Immunology*, **2022**, 13, 856906	8.4	0
302	Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages. *Vaccines*, **2022**, 10, 831	5.3	0
301	Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Survival in Human Macrophages.. *Frontiers in Immunology*, **2021**, 12, 712021	8.4	2
300	Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. *Frontiers in Immunology*, **2021**, 12, 725447	8.4	5
299	Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections. *Scientific Reports*, **2021**, 11, 19634	4.9	3
298	Conventional and Unconventional Lymphocytes in Immunity Against Mycobacterium tuberculosis **2021**, 133-168		
297	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Antigens. *Frontiers in Immunology*, **2021**, 12, 620622	8.4	2
296	In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination. *Npj Vaccines*, **2021**, 6, 81	9.5	2
295	Interleukin-6 and Mycobacterium tuberculosis dormancy antigens improve diagnosis of tuberculosis. *Journal of Infection*, **2021**, 82, 245-252	18.9	6
294	Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine. *Vaccines*, **2021**, 9,	5.3	2
293	The role of donor-unrestricted T-cells, innate lymphoid cells, and NK cells in anti-mycobacterial immunity. *Immunological Reviews*, **2021**, 301, 30-47	11.3	8
292	B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis. *Frontiers in Immunology*, **2021**, 12, 640168	8.4	12
291	Host-directed therapy to combat mycobacterial infections. *Immunological Reviews*, **2021**, 301, 62-83	11.3	14

290	Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and Quantification. *Frontiers in Immunology*, **2021**, 12, 637164	8.4	4
289	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. *Frontiers in Immunology*, **2021**, 12, 679973	8.4	3
288	Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate Improves Host Control of Serovar Typhimurium Infection in Human Macrophages. *Frontiers in Immunology*, **2021**, 12, 739938	8.4	0
287	The Transcriptomic Blueprint of in the Lung.. *Frontiers in Immunology*, **2021**, 12, 763364	8.4	0
286	Quantitative Rapid Test for Detection and Monitoring of Active Pulmonary Tuberculosis in Nonhuman Primates.. *Biology*, **2021**, 10,	4.9	1
285	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. *Molecular Immunology*, **2020**, 120, 187-195	4.3	6
284	Functional Inhibition of Host Histone Deacetylases (HDACs) Enhances and Anti-mycobacterial Activity in Human Macrophages and in Zebrafish. *Frontiers in Immunology*, **2020**, 11, 36	8.4	16
283	Cell-Mediated Immune Responses to -Expressed and Stage-Specific Antigens in Latent and Active Tuberculosis Across Different Age Groups. *Frontiers in Immunology*, **2020**, 11, 103	8.4	8
282	Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination. *Npj Vaccines*, **2020**, 5, 32	9.5	10
281	Analyzing the impact of Mycobacterium tuberculosis infection on primary human macrophages by combined exploratory and targeted metabolomics. *Scientific Reports*, **2020**, 10, 7085	4.9	13
280	A Trial of M72/AS01E Vaccine to Prevent Tuberculosis. *New England Journal of Medicine*, **2020**, 382, 1576-1577	59.5	3
279	An Internet-Based Psychological Intervention With a Serious Game to Improve Vitality, Psychological and Physical Condition, and Immune Function in Healthy Male Adults: Randomized Controlled Trial. *Journal of Medical Internet Research*, **2020**, 22, e14861	7.6	1
278	HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load. *Cell Reports*, **2020**, 33, 108451	10.6	4
277	Bioorthogonal Correlative Light-Electron Microscopy of in Macrophages Reveals the Effect of Antituberculosis Drugs on Subcellular Bacterial Distribution. *ACS Central Science*, **2020**, 6, 1997-2007	16.8	2
276	Tuberculosis causes highly conserved metabolic changes in human patients, mycobacteria-infected mice and zebrafish larvae. *Scientific Reports*, **2020**, 10, 11635	4.9	2
275	Combining host-derived biomarkers with patient characteristics improves signature performance in predicting tuberculosis treatment outcomes. *Communications Biology*, **2020**, 3, 359	6.7	6
274	Peptide Binding to HLA-E Molecules in Humans, Nonhuman Primates, and Mice Reveals Unique Binding Peptides but Remarkably Conserved Anchor Residues. *Journal of Immunology*, **2020**, 205, 2861-2872	5.3	6
273	Trends in diagnostic methods and treatment of latent tuberculosis infection in a tertiary care center from 2000 to 2017. *European Journal of Clinical Microbiology and Infectious Diseases*, **2020**, 39, 1329-1337	5.3	

272	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. *Scientific Reports*, **2020**, 10, 6290	4.9	5
271	Machine Learning Algorithms Evaluate Immune Response to Novel Antigens for Diagnosis of Tuberculosis. *Frontiers in Cellular and Infection Microbiology*, **2020**, 10, 594030	5.9	2
270	Host Blood RNA Transcript and Protein Signatures for Sputum-Independent Diagnostics of Tuberculosis in Adults. *Frontiers in Immunology*, **2020**, 11, 626049	8.4	3
269	Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. *Nature Medicine*, **2019**, 25, 255-262	50.5	130
268	Optimisation, harmonisation and standardisation of the direct mycobacterial growth inhibition assay using cryopreserved human peripheral blood mononuclear cells. *Journal of Immunological Methods*, **2019**, 469, 1-10	2.5	17
267	Whole-blood transcriptomic signatures induced during immunization by chloroquine prophylaxis and Plasmodium falciparum sporozoites. *Scientific Reports*, **2019**, 9, 8386	4.9	16
266	Oxidized low-density lipoprotein (oxLDL) supports Mycobacterium tuberculosis survival in macrophages by inducing lysosomal dysfunction. *PLoS Pathogens*, **2019**, 15, e1007724	7.6	19
265	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. *Frontiers in Immunology*, **2019**, 10, 527	8.4	26
264	Harnessing donor unrestricted T-cells for new vaccines against tuberculosis. *Vaccine*, **2019**, 37, 3022-3030	4.1	31
263	Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in Strains. *Frontiers in Immunology*, **2019**, 10, 195	8.4	4
262	Abnormalities suggestive of latent tuberculosis infection on chest radiography; how specific are they?. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2019**, 15, 100089	2.1	5
261	Effectiveness of Stress-Reducing Interventions on the Response to Challenges to the Immune System: A Meta-Analytic Review. *Psychotherapy and Psychosomatics*, **2019**, 88, 274-286	9.4	19
260	Radiological Signs of Latent Tuberculosis on Chest Radiography: A Systematic Review and Meta-Analysis. *Open Forum Infectious Diseases*, **2019**, 6,	1	5
259	Two-Hit T-Cell Stimulation Detects Infection in QuantiFERON Negative Tuberculosis Patients and Healthy Contacts From Ghana. *Frontiers in Immunology*, **2019**, 10, 1518	8.4	5
258	Mobilizing unconventional T cells. *Science*, **2019**, 366, 302-303	33.3	8
257	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. *Journal of Infectious Diseases*, **2019**, 220, S116-S125	7	17
256	Identification of a systemic interferon-inducible antimicrobial gene signature in leprosy patients undergoing reversal reaction. *PLoS Neglected Tropical Diseases*, **2019**, 13, e0007764	4.8	12
255	BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults. *JCI Insight*, **2019**, 4,	9.9	22

254	Mycobacterium tuberculosis clinical isolates of the Beijing and East-African Indian lineage induce fundamentally different host responses in mice compared to H37Rv. *Scientific Reports*, **2019**, 9, 19922	4.9	6
253	Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study. *Scientific Reports*, **2019**, 9, 17931	4.9	9
252	Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity. *Frontiers in Immunology*, **2019**, 10, 2479	8.4	17
251	Gene expression profiles classifying clinical stages of tuberculosis and monitoring treatment responses in Ethiopian HIV-negative and HIV-positive cohorts. *PLoS ONE*, **2019**, 14, e0226137	3.7	3
250	Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment. *Scientific Reports*, **2019**, 9, 18669	4.9	20
249	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. *Respirology*, **2018**, 23, 455-466	3.6	91
248	Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. *Lancet Infectious Diseases, The*, **2018**, 18, 738-748	25.5	42
247	Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1198-1208	10.2	125
246	Tuberculosis vaccines: Opportunities and challenges. *Respirology*, **2018**, 23, 359-368	3.6	54
245	Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis. *Scientific Reports*, **2018**, 8, 2675	4.9	27
244	Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. *Nature Communications*, **2018**, 9, 358	17.4	28
243	The SysteMHC Atlas project. *Nucleic Acids Research*, **2018**, 46, D1237-D1247	20.1	87
242	Vaccines for Leprosy and Tuberculosis: Opportunities for Shared Research, Development, and Application. *Frontiers in Immunology*, **2018**, 9, 308	8.4	13
241	A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. *Frontiers in Immunology*, **2018**, 9, 661	8.4	23
240	Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults. *Frontiers in Immunology*, **2018**, 9, 1035	8.4	18
239	Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During Infection and Correlate With Active Disease. *Frontiers in Immunology*, **2018**, 9, 1119	8.4	16
238	Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. *Seminars in Immunology*, **2018**, 39, 88-101	10.7	23
237	Host Gene Expression Kinetics During Treatment of Tuberculosis in HIV-Coinfected Individuals Is Independent of Highly Active Antiretroviral Therapy. *Journal of Infectious Diseases*, **2018**, 218, 1833-1846	7	10

236	Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. *BMC Infectious Diseases*, **2018**, 18, 26	4	26
235	Retinal Pigment Epithelial Cells Control Early Mycobacterium tuberculosis Infection via Interferon Signaling **2018**, 59, 1384-1395		13
234	Antibody glycosylation in inflammation, disease and vaccination. *Seminars in Immunology*, **2018**, 39, 102-110	10.7	74
233	NF-B/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. *JCI Insight*, **2018**, 3,	9.9	27
232	Detailed characterization of human Mycobacterium tuberculosis specific HLA-E restricted CD8 T cells. *European Journal of Immunology*, **2018**, 48, 293-305	6.1	25
231	Atypical Human Effector/Memory CD4 T Cells With a Naive-Like Phenotype. *Frontiers in Immunology* , **2018**, 9, 2832	8.4	17
230	Metabolite changes in blood predict the onset of tuberculosis. *Nature Communications*, **2018**, 9, 5208	17.4	66
229	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. *Frontiers in Immunology*, **2018**, 9, 2427	8.4	24
228	Mycobacterial growth inhibition is associated with trained innate immunity. *Journal of Clinical Investigation*, **2018**, 128, 1837-1851	15.9	96
227	A Systematic Review on Novel Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. *Frontiers in Immunology*, **2018**, 9, 2476	8.4	43
226	Cross-laboratory evaluation of multiplex bead assays including independent common reference standards for immunological monitoring of observational and interventional human studies. *PLoS ONE*, **2018**, 13, e0201205	3.7	8
225	A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. *International Journal of Infectious Diseases*, **2018**, 72, 63-68	10.5	8
224	Patients with Concurrent Tuberculosis and Diabetes Have a Pro-Atherogenic Plasma Lipid Profile. *EBioMedicine*, **2018**, 32, 192-200	8.8	18
223	Borderline QuantiFERON results and the distinction between specific responses and test variability. *Tuberculosis*, **2018**, 111, 102-108	2.6	10
222	Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. *Vaccine*, **2017**, 35, 1652-1661	4.1	33
221	Variable BCG efficacy in rhesus populations: Pulmonary BCG provides protection where standard intra-dermal vaccination fails. *Tuberculosis*, **2017**, 104, 46-57	2.6	58
220	A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. *Science Translational Medicine*, **2017**, 9,	17.5	37
219	Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. *Tuberculosis*, **2017**, 106, 25-32	2.6	10

218	Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis: Antigen Specificity, Function, Implications and Applications **2017**, 119-155		4
217	South Asian men have lower expression of IFN signalling genes in white adipose tissue and skeletal muscle compared with white men. *Diabetologia*, **2017**, 60, 2525-2528	10.3	2
216	Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of in Individuals with Latent Tuberculosis Infection. *Journal of Immunology Research*, **2017**, 2017, 1593143	4.5	13
215	Circulating Mycobacterium tuberculosis DosR latency antigen-specific, polyfunctional, regulatory IL10 Th17 CD4 T-cells differentiate latent from active tuberculosis. *Scientific Reports*, **2017**, 7, 11948	4.9	23
214	Immunological characterization of latent tuberculosis infection in a low endemic country. *Tuberculosis*, **2017**, 106, 62-72	2.6	11
213	Novel transcriptional signatures for sputum-independent diagnostics of tuberculosis in children. *Scientific Reports*, **2017**, 7, 5839	4.9	19
212	Proof of concept that most borderline Quantiferon results are true antigen-specific responses. *European Respiratory Journal*, **2017**, 50,	13.6	9
211	The effects of a psychological intervention directed at optimizing immune function: study protocol for a randomized controlled trial. *Trials*, **2017**, 18, 243	2.8	6
210	Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. *Frontiers in Immunology*, **2017**, 8, 294	8.4	39
209	TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development. *Frontiers in Immunology*, **2017**, 8, 1203	8.4	33
208	Molecular Signatures of Immunity and Immunogenicity in Infection and Vaccination. *Frontiers in Immunology*, **2017**, 8, 1563	8.4	12
207	MHC Ib molecule Qa-1 presents Mycobacterium tuberculosis peptide antigens to CD8+ T cells and contributes to protection against infection. *PLoS Pathogens*, **2017**, 13, e1006384	7.6	33
206	Rewiring cellular metabolism via the AKT/mTOR pathway contributes to host defence against Mycobacterium tuberculosis in human and murine cells. *European Journal of Immunology*, **2016**, 46, 2574-2586	6.1	87
205	Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. *Scientific Reports*, **2016**, 6, 18520	4.9	18
204	BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. *Scientific Reports*, **2016**, 6, 38841	4.9	6
203	Mycobacterium tuberculosis-specific CD4+ T-cell response is increased, and Treg cells decreased, in anthelmintic-treated patients with latent TB. *European Journal of Immunology*, **2016**, 46, 752-61	6.1	27
202	Dynamics of the T cell response to Mycobacterium tuberculosis DosR and Rpf antigens in a Colombian population of household contacts of recently diagnosed pulmonary tuberculosis patients. *Tuberculosis*, **2016**, 97, 97-107	2.6	6
201	Detection of IgG1 antibodies against Mycobacterium tuberculosis DosR and Rpf antigens in tuberculosis patients before and after chemotherapy. *Tuberculosis*, **2016**, 96, 65-70	2.6	11

200	A blood RNA signature for tuberculosis disease risk: a prospective cohort study. *Lancet, The*, **2016**, 387, 2312-2322	40	477
199	KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. *Tuberculosis*, **2016**, 97, 163-71	2.6	17
198	The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to Mycobacterium tuberculosis (Mtb) antigens in active TB patients and latently Mtb infected individuals. *Tuberculosis*, **2016**, 96, 131-40	2.6	16
197	Use of lateral flow assays to determine IP-10 and CCL4 levels in pleural effusions and whole blood for TB diagnosis. *Tuberculosis*, **2016**, 96, 31-6	2.6	25
196	Multi-center evaluation of a user-friendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. *Clinical Biochemistry*, **2016**, 49, 22-31	3.5	41
195	Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy. *JCI Insight*, **2016**, 1, e88843	9.9	23
194	Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. *PLoS Pathogens*, **2016**, 12, e1005687	7.6	89
193	Tuberculosis Biomarkers: From Diagnosis to Protection. *Gastroenterology Insights*, **2016**, 8, 6568	2.1	100
192	Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious Diseases. *Journal of Immunology Research*, **2016**, 2016, 2695396	4.5	52
191	Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment. *PLoS Neglected Tropical Diseases*, **2016**, 10, e0004701	4.8	15
190	Discriminative expression of whole blood genes in HIV patients with latent and active TB in Ethiopia. *Tuberculosis*, **2016**, 100, 25-31	2.6	5
189	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. *European Respiratory Journal*, **2016**, 48, 1751-1763	13.6	114
188	New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles. *Scientific Reports*, **2016**, 6, 37793	4.9	46
187	Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. *Thorax*, **2016**, 71, 785-94	7.3	89
186	Transcriptomic evidence for modulation of host inflammatory responses during febrile Plasmodium falciparum malaria. *Scientific Reports*, **2016**, 6, 31291	4.9	43
185	Multifunctional T Cell Response to DosR and Rpf Antigens Is Associated with Protection in Long-Term Mycobacterium tuberculosis-Infected Individuals in Colombia. *Vaccine Journal*, **2016**, 23, 813-824		19
184	Synthetic Long Peptide Derived from Mycobacterium tuberculosis Latency Antigen Rv1733c Protects against Tuberculosis. *Vaccine Journal*, **2015**, 22, 1060-9		21
183	Short-term high-fat diet increases macrophage markers in skeletal muscle accompanied by impaired insulin signalling in healthy male subjects. *Clinical Science*, **2015**, 128, 143-51	6.5	27

182	Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. *PLoS Pathogens*, **2015**, 11, e1004671	7.6	68
181	Dysregulation of Apoptosis Is a Risk Factor for Tuberculosis Disease Progression. *Journal of Infectious Diseases*, **2015**, 212, 1469-79	7	14
180	Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines. *European Journal of Immunology*, **2015**, 45, 1069-81	6.1	40
179	Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. *Vaccine Journal*, **2015**, 22, 778-88		36
178	Focused human gene expression profiling using dual-color reverse transcriptase multiplex ligation-dependent probe amplification. *Vaccine*, **2015**, 33, 5282-8	4.1	15
177	Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination. *Frontiers in Immunology*, **2015**, 6, 217	8.4	99
176	Pro- and anti-inflammatory cytokines against Rv2031 are elevated during latent tuberculosis: a study in cohorts of tuberculosis patients, household contacts and community controls in an endemic setting. *PLoS ONE*, **2015**, 10, e0124134	3.7	27
175	Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines. *PLoS ONE*, **2015**, 10, e0138042	3.7	42
174	Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus. *Immunological Reviews*, **2015**, 264, 121-37	11.3	62
173	Ebola vaccine R&D: Filling the knowledge gaps. *Science Translational Medicine*, **2015**, 7, 317ps24	17.5	37
172	The C-type lectin receptor CLECSF8/CLEC4D is a key component of anti-mycobacterial immunity. *Cell Host and Microbe*, **2015**, 17, 252-9	23.4	71
171	Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis. *EBioMedicine*, **2015**, 2, 172-9	8.8	26
170	Clinical immunology and multiplex biomarkers of human tuberculosis. *Cold Spring Harbor Perspectives in Medicine*, **2014**, 5,	5.4	27
169	Longitudinal immune responses and gene expression profiles in type 1 leprosy reactions. *Journal of Clinical Immunology*, **2014**, 34, 245-55	5.7	49
168	Differential gene expression of activating Fc receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity. *Clinical Microbiology and Infection*, **2014**, 20, O230-8	9.5	54
167	TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: How can big data help? *Vaccine*, **2014**, 32, 4365-4368	4.1	4
166	Combination of gene expression patterns in whole blood discriminate between tuberculosis infection states. *BMC Infectious Diseases*, **2014**, 14, 257	4	21
165	The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4+ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs. *Vaccine*, **2014**, 32, 3580-8	4.1	18

164	The DNA damage-regulated autophagy modulator DRAM1 links mycobacterial recognition via TLR-MYD88 to autophagic defense [corrected]. *Cell Host and Microbe*, **2014**, 15, 753-67	23.4	112
163	CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live Mycobacterium bovis-BCG activation of human cells. *PLoS ONE*, **2014**, 9, e94192	3.7	28
162	Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method. *PLoS ONE*, **2014**, 9, e99203	3.7	11
161	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. *Vaccine*, **2014**, 32, 7098-107	4.1	152
160	Diagnosis of childhood tuberculosis and host RNA expression in Africa. *New England Journal of Medicine*, **2014**, 370, 1712-1723	59.2	229
159	Field-evaluation of a new lateral flow assay for detection of cellular and humoral immunity against Mycobacterium leprae. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2845	4.8	46
158	T-cell regulation in lepromatous leprosy. *PLoS Neglected Tropical Diseases*, **2014**, 8, e2773	4.8	54
157	Immunogenicity of 60 novel latency-related antigens of Mycobacterium tuberculosis. *Frontiers in Microbiology*, **2014**, 5, 517	5.7	53
156	Use of resuscitation-promoting factor proteins improves the sensitivity of culture-based tuberculosis testing in special samples. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 612-4	10.2	15
155	Significance of antigen and epitope specificity in tuberculosis. *Frontiers in Immunology*, **2014**, 5, 524	8.4	3
154	Innovative Strategies to Identify M. tuberculosis Antigens and Epitopes Using Genome-Wide Analyses. *Frontiers in Immunology*, **2014**, 5, 256	8.4	41
153	The influence of influenza virus infections on the development of tuberculosis. *Tuberculosis*, **2013**, 93, 338-42	2.6	20
152	Interferon-γ responses to Mycobacterium tuberculosis Rpf proteins in contact investigation. *Tuberculosis*, **2013**, 93, 612-7	2.6	11
151	An unbiased genome-wide Mycobacterium tuberculosis gene expression approach to discover antigens targeted by human T cells expressed during pulmonary infection. *Journal of Immunology*, **2013**, 190, 1659-71	5.3	59
150	CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8(+) CD39(+) regulatory T cells. *European Journal of Immunology*, **2013**, 43, 1925-32	6.1	39
149	Low induction of proinflammatory cytokines parallels evolutionary success of modern strains within the Mycobacterium tuberculosis Beijing genotype. *Infection and Immunity*, **2013**, 81, 3750-6	3.7	46
148	Analysis of host responses to Mycobacterium tuberculosis antigens in a multi-site study of subjects with different TB and HIV infection states in sub-Saharan Africa. *PLoS ONE*, **2013**, 8, e74080	3.7	42
147	Recombinant ESAT-6-CFP10 Fusion Protein Induction of Th1/Th2 Cytokines and FoxP3 Expressing Treg Cells in Pulmonary TB. *PLoS ONE*, **2013**, 8, e68121	3.7	19

146	A helicopter perspective on TB biomarkers: pathway and process based analysis of gene expression data provides new insight into TB pathogenesis. *PLoS ONE*, **2013**, 8, e73230	3.7	74
145	Ten challenges for TB biomarkers. *Tuberculosis*, **2012**, 92 Suppl 1, S17-20	2.6	42
144	Polymorphisms in SP110 are not associated with pulmonary tuberculosis in Indonesians. *Infection, Genetics and Evolution*, **2012**, 12, 1319-23	4.5	18
143	T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. *Tuberculosis*, **2012**, 92, 148-59	2.6	43
142	A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians. *BMC Medical Genetics*, **2012**, 13, 5	2.1	78
141	A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice. *Vaccine*, **2012**, 30, 7513-21	4.1	21
140	New pathways of protective and pathological host defense to mycobacteria. *Trends in Microbiology*, **2012**, 20, 419-28	12.4	113
139	T cell assays and MIATA: the essential minimum for maximum impact. *Immunity*, **2012**, 37, 1-2	32.3	117
138	Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in patients with active pulmonary tuberculosis. *Vaccine Journal*, **2012**, 19, 1907-15		45
137	Potential of Mycobacterium tuberculosis resuscitation-promoting factors as antigens in novel tuberculosis sub-unit vaccines. *Microbes and Infection*, **2012**, 14, 86-95	9.3	39
136	Common variants at 11p13 are associated with susceptibility to tuberculosis. *Nature Genetics*, **2012**, 44, 257-9	36.3	156
135	Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis. *PLoS ONE*, **2012**, 7, e45839	3.7	168
134	Mycobacterium leprae virulence-associated peptides are indicators of exposure to M. leprae in Brazil, Ethiopia and Nepal. *Memorias Do Instituto Oswaldo Cruz*, **2012**, 107 Suppl 1, 112-23	2.6	12
133	Vaccines against tuberculosis: where are we and where do we need to go?. *PLoS Pathogens*, **2012**, 8, e1002607	7.6	325
132	Peptides Derived from Mycobacterium leprae ML1601c Discriminate between Leprosy Patients and Healthy Endemic Controls. *Journal of Tropical Medicine*, **2012**, 2012, 132049	2.4	11
131	Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. *PLoS ONE*, **2012**, 7, e38501	3.7	43
130	Simultaneous immunization against tuberculosis. *PLoS ONE*, **2011**, 6, e27477	3.7	26
129	Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. *Vaccine*, **2011**, 29, 2100-9	4.1	103

128	Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. *Vaccine*, **2011**, 29, 4761-70	4.1	54
127	Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens. *Vaccine*, **2011**, 29, 8740-4	4.1	27
126	Lateral flow assay for simultaneous detection of cellular- and humoral immune responses. *Clinical Biochemistry*, **2011**, 44, 1241-6	3.5	75
125	A high-throughput screen for tuberculosis progression. *PLoS ONE*, **2011**, 6, e16779	3.7	85
124	Double- and monofunctional CD4+ and CD8+ T-cell responses to Mycobacterium tuberculosis DosR antigens and peptides in long-term latently infected individuals. *European Journal of Immunology*, **2011**, 41, 2925-36	6.1	73
123	Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD8+ T cells in human tuberculosis. *Journal of Immunology*, **2011**, 186, 1068-80	5.3	40
122	Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes. *Journal of Liposome Research*, **2011**, 21, 286-95	6.1	4
121	Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. *Vaccine Journal*, **2011**, 18, 676-83		54
120	ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria. *Journal of Immunology*, **2011**, 187, 1393-402	5.3	11
119	CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. *Infection and Immunity*, **2011**, 79, 3328-37	3.7	45
118	Identification of probable early-onset biomarkers for tuberculosis disease progression. *PLoS ONE*, **2011**, 6, e25230	3.7	32
117	Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. *PLoS ONE*, **2011**, 6, e27539	3.7	48
116	Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays. *Vaccine Journal*, **2010**, 17, 993-1004		24
115	Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 17686-91	11.5	181
114	Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. *PLoS Pathogens*, **2010**, 6, e1000782	7.6	111
113	First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. *Hum Vaccin*, **2010**, 6, 1007-15		50
112	Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. *Vaccine*, **2010**, 28, 3571-81	4.1	164
111	Increased IgG1, IFN-gamma, TNF-alpha and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. *International Immunology*, **2010**, 22, 775-82	4.9	61

110	Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. *International Journal of Cancer*, **2010**, 127, 899-909	7.5	70
109	Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. *European Journal of Immunology*, **2010**, 40, 2211-20	6.1	227
108	The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. *Microbes and Infection*, **2010**, 12, 910-8	9.3	50
107	MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. *PLoS ONE*, **2009**, 4, e5264	3.7	167
106	Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. *PLoS ONE*, **2009**, 4, e7972	3.7	41
105	Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteria. *Infection and Immunity*, **2009**, 77, 5071-9	3.7	41
104	Infection with Mycobacterium tuberculosis Beijing genotype strains is associated with polymorphisms in SLC11A1/NRAMP1 in Indonesian patients with tuberculosis. *Journal of Infectious Diseases*, **2009**, 200, 1671-4	7	62
103	Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. *Vaccine Journal*, **2009**, 16, 1203-12		129
102	Transcriptional and inflammasome-mediated pathways for the induction of IL-1beta production by Mycobacterium tuberculosis. *European Journal of Immunology*, **2009**, 39, 1914-22	6.1	59
101	Overcoming the global crisis: "yes, we can", but also for TB ... ?. *European Journal of Immunology*, **2009**, 39, 2014-20	6.1	37
100	Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. *Vaccine*, **2009**, 27, 4010-7	4.1	81
99	Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. *PLoS ONE*, **2009**, 4, e5528	3.7	82
98	Genetic deficiencies of innate immune signalling in human infectious disease. *Lancet Infectious Diseases, The*, **2009**, 9, 688-98	25.5	87
97	Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. *PLoS ONE*, **2009**, 4, e5590	3.7	103
96	Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. *Human Immunology*, **2008**, 69, 760-70	2.3	104
95	Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. *Journal of Immunology*, **2008**, 181, 2220-6	5.3	190
94	The ESX-5 secretion system of Mycobacterium marinum modulates the macrophage response. *Journal of Immunology*, **2008**, 181, 7166-75	5.3	105
93	Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. *PLoS Genetics*, **2008**, 4, e1000218	6	193

92	Influenza virus vaccination induces interleukin-12/23 receptor beta 1 (IL-12/23R beta 1)-independent production of gamma interferon (IFN-gamma) and humoral immunity in patients with genetic deficiencies in IL-12/23R beta 1 or IFN-gamma receptor I. *Vaccine Journal*, **2008**, 15, 1171-5		10
91	Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2008**, 8, 15-29	2.2	22
90	Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. *Biological Chemistry*, **2008**, 389, 497-511	4.5	39
89	The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clinical Infectious Diseases*, **2007**, 45, 428-35	11.6	219
88	Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. *Nature*, **2007**, 450, 725-30	50.4	243
87	Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gamma levels correlate with tuberculosis disease activity in adults. *Tuberculosis*, **2007**, 87, 312-21	2.6	43
86	Association of polymorphisms in IL-12/IFN-gamma pathway genes with susceptibility to pulmonary tuberculosis in Indonesia. *Tuberculosis*, **2007**, 87, 303-11	2.6	41
85	Two patients with complete defects in interferon gamma receptor-dependent signaling. *Journal of Clinical Immunology*, **2007**, 27, 490-6	5.7	24
84	T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. *Infection and Immunity*, **2007**, 75, 2914-21	3.7	100
83	Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8029-34	11.5	165
82	Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. *Infection and Immunity*, **2007**, 75, 820-9	3.7	132
81	Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. *Infection and Immunity*, **2007**, 75, 941-9	3.7	116
80	Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation. *Vaccine Journal*, **2007**, 14, 880-5		97
79	Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. *Infection and Immunity*, **2007**, 75, 3523-30	3.7	89
78	Detection of Mycobacterium leprae infection employing a combinatorial approach of anti-45 kDa and modified anti-PGL-I antibody detection assays. *Journal of Medical Microbiology*, **2007**, 56, 1129-1130	3.2	2
77	Assessment of Cross-Reactivity between Mycobacterium bovis and M. kansasii ESAT-6 and CFP-10 at the T-Cell Epitope Level. *Vaccine Journal*, **2007**, 14, 1536-1536		1
76	Serological heterogeneity against various Mycobacterium leprae antigens and its use in serodiagnosis of leprosy patients. *Journal of Medical Microbiology*, **2007**, 56, 1259-1261	3.2	2
75	Monokine induced by interferon gamma and IFN-gamma response to a fusion protein of Mycobacterium tuberculosis ESAT-6 and CFP-10 in Brazilian tuberculosis patients. *Microbes and Infection*, **2006**, 8, 45-51	9.3	45

74	The search for a tuberculosis vaccine: an elusive quest?. *Tuberculosis*, **2006**, 86, 41-6	2.6	10
73	Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. *European Journal of Immunology*, **2006**, 36, 661-70	6.1	201
72	Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. *Vaccine Journal*, **2006**, 13, 179-86		159
71	Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. *Journal of Leukocyte Biology*, **2006**, 79, 285-93	6.5	277
70	HLA and leprosy in the pre and postgenomic eras. *Human Immunology*, **2006**, 67, 439-45	2.3	31
69	Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. *Microbes and Infection*, **2006**, 8, 2052-60	9.3	220
68	Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. *Microbes and Infection*, **2006**, 8, 1167-73	9.3	44
67	Presentation of interleukin-12/-23 receptor beta1 deficiency with various clinical symptoms of Salmonella infections. *Journal of Clinical Immunology*, **2006**, 26, 1-6	5.7	50
66	Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. *Human Immunology*, **2005**, 66, 13-20	2.3	324
65	T cell immune responses to mycobacterial antigens in Brazilian tuberculosis patients and controls. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **2005**, 99, 699-707	2	20
64	Control of human host immunity to mycobacteria. *Tuberculosis*, **2005**, 85, 53-64	2.6	141
63	NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. *PLoS Pathogens*, **2005**, 1, 279-85	7.6	275
62	Postgenomic approach to identify novel Mycobacterium leprae antigens with potential to improve immunodiagnosis of infection. *Infection and Immunity*, **2005**, 73, 5636-44	3.7	51
61	Molecular complementation of IL-12Rbeta1 deficiency reveals functional differences between IL-12Rbeta1 alleles including partial IL-12Rbeta1 deficiency. *Human Molecular Genetics*, **2005**, 14, 3847-53	5.6	30
60	Leprosy bacillus triggers the wrong cells. *International Journal of Leprosy and Other Mycobacterial Diseases*, **2005**, 73, 208-10		1
59	Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 4560-5	11.5	683
58	Pneumonia caused by Mycobacterium kansasii in a series of patients without recognised immune defect. *Clinical Microbiology and Infection*, **2004**, 10, 738-48	9.5	29
57	Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. *Genes and Immunity*, **2004**, 5, 592-5	4.4	54

56	Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. *Lancet Infectious Diseases, The*, **2004**, 4, 739-49	25.5	169
55	Study of the antibody response against Mycobacterium tuberculosis antigens in Warao Amerindian children in Venezuela. *Memorias Do Instituto Oswaldo Cruz*, **2004**, 99, 517-24	2.6	20
54	DISSEMINATED MYCOBACTERIUM PEREGRINUM INFECTION IN A CHILD WITH COMPLETE INTERFERON-GAMMA RECEPTOR-1 DEFICIENCY. *Pediatric Infectious Disease Journal*, **2003**, 22, 378-380	3.4	36
53	Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function. *Immunogenetics*, **2003**, 54, 817-29	3.2	46
52	Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. *European Journal of Immunology*, **2003**, 33, 59-69	6.1	73
51	IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency. *European Journal of Immunology*, **2003**, 33, 3393-7	6.1	28
50	Human deficiencies in type-1 cytokine receptors reveal the essential role of type-1 cytokines in immunity to intracellular bacteria. *Advances in Experimental Medicine and Biology*, **2003**, 531, 279-94	3.6	23
49	Kinetics of T cell-activation molecules in response to Mycobacterium tuberculosis antigens. *Memorias Do Instituto Oswaldo Cruz*, **2002**, 97, 1097-9	2.6	14
48	Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. *Nature Genetics*, **2002**, 32, 97-105	36.3	210
47	Role of tumor necrosis factor-alpha and interleukin-10 promoter gene polymorphisms in leprosy. *Journal of Infectious Diseases*, **2002**, 186, 1687-91	7	100
46	Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. *Infection and Immunity*, **2002**, 70, 5446-53	3.7	134
45	Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosis. *Infection and Immunity*, **2002**, 70, 2544-8	3.7	103
44	Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. *Journal of Infectious Diseases*, **2002**, 186, 1797-807	7	138
43	Human host defense and cytokines in mycobacterial infectious diseases: interleukin-18 cannot compensate for genetic defects in the interleukin-12 system. *Clinical Infectious Diseases*, **2002**, 35, 210-2	11.6	115
42	Innate immunity to Mycobacterium tuberculosis. *Clinical Microbiology Reviews*, **2002**, 15, 294-309	34	432
41	Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. *International Journal of Cancer*, **2001**, 91, 612-8	7.5	122
40	Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. *Vaccine Journal*, **2001**, 8, 1089-96		59
39	Presence of human T-cell responses to the Mycobacterium leprae 45-kilodalton antigen reflects infection with or exposure to M. leprae. *Vaccine Journal*, **2001**, 8, 604-11		5

38	Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. *Journal of Infectious Diseases*, **2001**, 183, 175-6	7	66
37	Mycobacterium leprae-specific, HLA class II-restricted killing of human Schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy. *Journal of Immunology*, **2001**, 166, 5883-8	5.3	60
36	Repeatedly negative tuberculin skin tests followed by active tuberculosis in an immunocompetent individual. *Netherlands Journal of Medicine*, **2001**, 58, 76-81	0.5	3
35	Multifocal osteomyelitis caused by nontuberculous mycobacteria in patients with a genetic defect of the interferon-gamma receptor. *Netherlands Journal of Medicine*, **2001**, 59, 140-51	0.5	41
34	Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. *Immunology and Cell Biology*, **2000**, 78, 349-55	5	36
33	Human deficiencies in type 1 cytokine receptors reveal the essential role of type 1 cytokines in immunity to intracellular bacteria. *Microbes and Infection*, **2000**, 2, 1559-66	9.3	31
32	Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans. *Journal of Immunology*, **2000**, 165, 6463-71	5.3	142
31	Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. *Infection and Immunity*, **2000**, 68, 3314-21	3.7	158
30	Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. *Journal of Experimental Medicine*, **2000**, 192, 517-28	16.6	70
29	Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. *Protein Expression and Purification*, **2000**, 18, 95-9	2	182
28	Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. *Blood*, **2000**, 95, 3162-3167	2.2	134
27	Allorecognition of artificial nerve guides filed with human Schwann cells: an in vitro piloot study. *Transplantation*, **2000**, 69, 455-6	1.8	1
26	Limitations of homology searching for identification of T-cell antigens with library derived mimicry epitopes. *Vaccine*, **1999**, 18, 204-8	4.1	5
25	The mammalian cell entry operon 1 (mce1) of mycobacterium leprae and mycobacterium tuberculosis. *Microbial Pathogenesis*, **1999**, 27, 173-7	3.8	22
24	HLA-DR/DQ transgenic, class II deficient mice as a novel model to select for HSP T cell epitopes with immunotherapeutic or preventative vaccine potential. *Biotherapy (Dordrecht, Netherlands)*, **1998**, 10, 191-6		10
23	Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. *Trends in Immunology*, **1998**, 19, 491-4		255
22	Altered peptide ligands of islet autoantigen Imogen 38 inhibit antigen specific T cell reactivity in human type-1 diabetes. *Journal of Autoimmunity*, **1998**, 11, 353-61	15.5	26
21	Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. *Science*, **1998**, 280, 1435-8	33.3	714

20	Modulation of protective and pathological immunity in mycobacterial infections. *International Archives of Allergy and Immunology*, **1997**, 113, 400-8	3.7	8
19	HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. *Current Biology*, **1997**, 7, 950-7	6.3	141
18	A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. *Journal of Immunological Methods*, **1997**, 200, 89-97	2.5	28
17	A novel, highly efficient peptide-HLA class I binding assay using unfolded heavy chain molecules: identification of HIV-1 derived peptides that bind to HLA-A*0201 and HLA-A*0301. *Journal of Immunological Methods*, **1997**, 205, 201-9	2.5	17
16	A DR17-restricted T cell epitope from a secreted Mycobacterium tuberculosis antigen only binds to DR17 molecules at neutral pH. *European Journal of Immunology*, **1997**, 27, 842-7	6.1	13
15	Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. *European Journal of Immunology*, **1997**, 27, 2426-35	6.1	274
14	Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells. *Advances in Experimental Medicine and Biology*, **1997**, 417, 171-4	3.6	31
13	Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. *European Journal of Immunology*, **1996**, 26, 2067-74	6.1	187
12	Immunological and functional characterization of Mycobacterium leprae protein antigens: an overview. *Molecular Microbiology*, **1995**, 18, 791-800	4.1	28
11	T cell receptor and peptide-contacting residues in the HLA-DR17(3) beta 1 chain. *European Journal of Immunology*, **1994**, 24, 3241-4	6.1	18
10	The biologic importance of conserved major histocompatibility complex class II motifs in primates. *Human Immunology*, **1993**, 38, 201-5	2.3	14
9	Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. *European Journal of Immunology*, **1992**, 22, 107-13	6.1	49
8	Regulation of mycobacterial heat-shock protein-reactive T cells by HLA class II molecules: lessons from leprosy. *Immunological Reviews*, **1991**, 121, 171-91	11.3	56
7	Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein. *European Journal of Immunology*, **1990**, 20, 369-77	6.1	66
6	Human suppressor T cell clones lack CD28. *European Journal of Immunology*, **1990**, 20, 1281-8	6.1	23
5	Mycobacterium leprae-specific protein antigens defined by cloned human helper T cells. *Nature*, **1986**, 319, 66-8	50.4	109
4	Cloned suppressor T cells from a lepromatous leprosy patient suppress Mycobacterium leprae reactive helper T cells. *Nature*, **1986**, 322, 462-4	50.4	125
3	Identification of reduced host transcriptomic signatures for tuberculosis and digital PCR-based validation and quantification		5

2	Effects of BCG vaccination on donor unrestricted T cells in humans	1
1	Single-Cell Mechanical Characterization of Human Macrophages. *Advanced NanoBiomed Research*,2100133	1